Acrivon Therapeutics Files Q1 2025 10-Q
Ticker: ACRV · Form: 10-Q · Filed: May 14, 2025 · CIK: 1781174
| Field | Detail |
|---|---|
| Company | Acrivon Therapeutics, Inc. (ACRV) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
ACRV Q1 2025 10-Q filed. Financials updated, cash & investments detailed.
AI Summary
Acrivon Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and results of operations, including details on its cash, investments, and equity. Key financial data points such as retained earnings and accumulated other comprehensive income were disclosed for the periods ending December 31, 2024, and March 31, 2025.
Why It Matters
This filing provides investors with an update on Acrivon Therapeutics' financial health and operational performance for the first quarter of 2025, crucial for assessing the company's stability and future prospects.
Risk Assessment
Risk Level: medium — As a biotechnology company, Acrivon Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market acceptance, which are not fully detailed in this summary but are typical for the sector.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 2025-05-14 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
- 2024-12-31 — Previous Year End Date (Provides a comparative point for financial metrics from the prior fiscal year-end.)
Key Players & Entities
- Acrivon Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250514 (date) — Filing date
- 001-41551 (dollar_amount) — SEC file number
- WATERTOWN, MA (location) — Company's business and mailing address
FAQ
What is the primary business of Acrivon Therapeutics, Inc.?
Acrivon Therapeutics, Inc. is primarily involved in the pharmaceutical preparations industry, as indicated by its Standard Industrial Classification code [2834].
What is the SEC file number for Acrivon Therapeutics?
The SEC file number for Acrivon Therapeutics is 001-41551.
Where is Acrivon Therapeutics, Inc. located?
Acrivon Therapeutics, Inc. is located at 480 Arsenal Way, Suite 100, Watertown, MA 02472.
What period does this 10-Q filing cover?
This 10-Q filing covers the period ending March 31, 2025.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted to the SEC on May 14, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Acrivon Therapeutics, Inc. (ACRV).